CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Underwritten Equity Offering	At-The-Market Offering	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Common Stock Underwritten Equity Offering	Common Stock At-The-Market Offering	Additional Paid in Capital	Additional Paid in Capital Underwritten Equity Offering	Additional Paid in Capital At-The-Market Offering	Additional Paid in Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020					52,248,431
Beginning balance at Dec. 31, 2020	$ 211,213				$ 5			$ 797,985				$ (902)	$ (585,875)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share based compensation	7,479							7,479
Issuance of common stock under the equity incentive plan and proceeds from exercise (in shares)					470,613
Issuance of common stock under the equity incentive plan and proceeds from exercise	2,755							2,755
Issuance of common stock (in shares)						7,532,500	184,186
Issuance of common stock, net of offering costs		$ 189,377	$ 4,878			$ 1	$ 0		$ 189,376	$ 4,878
Unrealized loss on marketable debt securities	(463)											(463)
Foreign currency translation adjustments	1,103											1,103
Employee stock purchase program purchase and expense	214							214
Net loss	(53,867)												(53,867)
Ending balance (in shares) at Mar. 31, 2021					60,435,730
Ending balance at Mar. 31, 2021	$ 362,689				$ 6			1,002,687				(262)	(639,742)
Accounting Standards Update [Extensible List]	Accounting Standards Update 2020-06 Cumulative Effect, Period of Adoption [Member]
Beginning balance (in shares) at Dec. 31, 2020					52,248,431
Beginning balance at Dec. 31, 2020	$ 211,213				$ 5			797,985				(902)	(585,875)
Ending balance (in shares) at Dec. 31, 2021					62,491,498
Ending balance at Dec. 31, 2021	302,112			$ (44,720)	$ 6			1,068,634			$ (74,945)	(562)	(765,966)	$ 30,225
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share based compensation	7,935							7,935
Issuance of common stock under the equity incentive plan and proceeds from exercise (in shares)					317,179
Issuance of common stock under the equity incentive plan and proceeds from exercise	122							122
Issuance of common stock (in shares)							701,600
Issuance of common stock, net of offering costs			$ 19,545							$ 19,545
Unrealized loss on marketable debt securities	(1,204)											(1,204)
Foreign currency translation adjustments	71											71
Employee stock purchase program purchase and expense	251							251
Net loss	(75,971)												(75,971)
Ending balance (in shares) at Mar. 31, 2022					63,510,277
Ending balance at Mar. 31, 2022	$ 208,141				$ 6			$ 1,021,542				$ (1,695)	$ (811,712)